Derrick Siu

Employment

• NHMRC Clinical Trials Centre Oncology Research Fellow
• Illawarra Shoalhaven Local Health District Medical Oncologist

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (22)

• Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-I…
  The Lancet Oncology 2026 DOI: 10.1016/s1470-2045(26)00532-2
  +Save
• Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program
  Derrick Ho Wai Siu, Frank P. Y. Lin, David Morgan Thomas +6 more
  Future Oncology 2026 DOI: 10.1080/14796694.2026.2688570
  +Save
• LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
  Annals of Oncology 2025 DOI: 10.1016/j.annonc.2025.09.095
  +Save
• 260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free su…
  Annals of Oncology 2025 DOI: 10.1016/j.annonc.2025.05.275
  +Save
• AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Tria…
  Clinical Colorectal Cancer 2025 DOI: 10.1016/j.clcc.2024.11.003
  +Save
• Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours.
  Journal of Clinical Oncology 2025 DOI: 10.1200/jco.2025.43.16_suppl.tps4224
  +Save
• AGITG ASCEND: Randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: Initial results.
  Journal of Clinical Oncology 2025 DOI: 10.1200/jco.2025.43.4_suppl.728
  +Save
• AGITG SPAR: A randomized, placebo-controlled, phase II trial of simvastatin in addition to neoadjuvant chemotherapy and radiation for rectal cancer.
  Journal of Clinical Oncology 2025 DOI: 10.1200/jco.2025.43.4_suppl.141
  +Save
• Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer
  Exploration of Targeted Anti-tumor Therapy 2024 DOI: 10.37349/etat.2024.00273
  +Save
• Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials
  Current Medical Research and Opinion 2024 DOI: 10.1080/03007995.2024.2376129
  +Save
• Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials
  Derrick Ho Wai Siu, Frank P. Y. Lin, Doah Cho +4 more
  JCO Precision Oncology 2024 DOI: 10.1200/PO.23.00317
  +Save
• Prognostic value of patient reported outcomes in advanced gastro‐oesophageal cancer: a systematic review
  Internal Medicine Journal 2023 DOI: 10.1111/imj.16209
  +Save
• ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial
  ESMO Gastrointestinal Oncology 2023 DOI: 10.1016/j.esmogo.2023.07.001
  +Save
• 131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
  Annals of Oncology 2022 DOI: 10.1016/j.annonc.2022.10.167
  +Save
• Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review
  Immunotherapy 2022 DOI: 10.2217/imt-2021-0225
  +Save
• Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future
  Cancers 2022 DOI: 10.3390/cancers14061406
  +Save
• Prognostic value of patient reported outcomes (PROs) in advanced gastroesophageal cancer (GO): A systematic review.
  Journal of Clinical Oncology 2022 DOI: 10.1200/jco.2022.40.4_suppl.251
  +Save
• Clinical and molecular profile of young adults with early‐onset colorectal cancer: Experience from four Australian tertiary centers
  Asia-Pacific Journal of Clinical Oncology 2022 DOI: 10.1111/ajco.13745
  +Save
• MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
  BMC Cancer 2021 DOI: 10.1186/s12885-021-08644-4
  +Save
• 292 Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management
  Regular and young investigator award abstracts 2020 DOI: 10.1136/jitc-2020-sitc2020.0292
  +Save